This recent article demonstrates that the new generation anticoagulants are as effective as our old gold standard but with less bleeding risk.

The study compared a new Xa inhibitor with our present standard of care — low molecular weight heparin plus warfarin/Coumadin — for pulmonary embolism and acute venous thromboembolism.  As I have mentioned in a prior newsletter, the newer generation blood thinners are game changers.   If you would like to learn more, these medication innovations were also discussed in a past newletter article explaining Atrial Fibrillation.